Aldosterone-producing adenoma with seizures and neurological abnormalities
Also known as APA with seizures and neurological abnormalities, Conn adenoma with seizures and neurological abnormalities, aldosterone-secreting adenoma with seizures and neurological abnormalities, complex neurodevelopmental disorder with or without aldosteronism+6 more
APA with seizures and neurological abnormalities, Conn adenoma with seizures and neurological abnormalities, aldosterone-secreting adenoma with seizures and neurological abnormalities, complex neurodevelopmental disorder with or without aldosteronism, primary aldosteronism, seizures, and neurologic abnormalities, Conn adenoma, PASNA, aldosterone-secreting adenoma, aldosteronoma, primary aldosteronism due to Conn adenoma.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 4 clinical trials expected to report results, the earliest in Q3 2027.
- Q3 2027A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy and Safety of Baxdrostat in Adult Participants With Primary Aldosteronism
- Q4 2027A Phase III, Randomized, Double-blinded Study of the Efficacy and Safety of LEvetiracetam to Prevent Seizures in Symptomatic Alzheimer's Disease in Adults With Down Syndrome (the LESS-AD Trial).
- Q3 2028Modulation of PSMA Expression in Castration Sensitive and Castration Resistant Prostate Cancer in Response to Hormonal Therapy
- Q2 2031Short Versus Long-term Levetiracetam in Brain Tumors: A Phase 3 Randomized Controlled Trial (LIBRA)
Clinical MilestonesViewHide
- 2026-07-06A Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy and Safety of Baxdrostat in Adult Participants With Primary AldosteronismResults expected Q3 2027
- 2026-02-13Short Versus Long-term Levetiracetam in Brain Tumors: A Phase 3 Randomized Controlled Trial (LIBRA)Results expected Q2 2031
- 2026-01-12A Phase III, Randomized, Double-blinded Study of the Efficacy and Safety of LEvetiracetam to Prevent Seizures in Symptomatic Alzheimer's Disease in Adults With Down Syndrome (the LESS-AD Trial).Results expected Q4 2027
- 2025-10-24Modulation of PSMA Expression in Castration Sensitive and Castration Resistant Prostate Cancer in Response to Hormonal TherapyResults expected Q3 2028
- 2026-06-10A Multicenter Open-Label Extension Study to Evaluate the Long-Term Safety of Cenobamate Adjunctive Therapy in Subjects With Primary Generalized Tonic-Clonic SeizuresCompleted
- 2026-02-03A Randomized, Double-blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Focal-Onset SeizuresCompleted
- 2025-11-12Frequency of Recurrence of Seizures With Intravenous Versus Intramuscular Magnesium Sulphate in Women With EclampsiaCompleted
- 2026-07-06ClinicalA Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy and Safety of Baxdrostat in Adult Participants With Primary AldosteronismResults expected Q3 2027
- 2026-06-10ClinicalA Multicenter Open-Label Extension Study to Evaluate the Long-Term Safety of Cenobamate Adjunctive Therapy in Subjects With Primary Generalized Tonic-Clonic SeizuresCompleted
- 2026-05-13ClinicalA Prospective, Randomized, Open-label Clinical Trial to Assess the Safety of Simultaneous Vaccination With mRNA COVID-19 Vaccine and Other Vaccines in Young Children Aged 6 Months to <5 Years.Results posted
- 2026-02-13ClinicalShort Versus Long-term Levetiracetam in Brain Tumors: A Phase 3 Randomized Controlled Trial (LIBRA)Results expected Q2 2031
- 2026-02-03ClinicalA Randomized, Double-blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Focal-Onset SeizuresCompleted
- 2026-01-12ClinicalA Phase III, Randomized, Double-blinded Study of the Efficacy and Safety of LEvetiracetam to Prevent Seizures in Symptomatic Alzheimer's Disease in Adults With Down Syndrome (the LESS-AD Trial).Results expected Q4 2027
- 2025-11-12ClinicalFrequency of Recurrence of Seizures With Intravenous Versus Intramuscular Magnesium Sulphate in Women With EclampsiaCompleted
- 2025-10-24ClinicalModulation of PSMA Expression in Castration Sensitive and Castration Resistant Prostate Cancer in Response to Hormonal TherapyResults expected Q3 2028
Clinical trials
The current development programme across all trial phases.
Associated genes
Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.
Disease biology
Proteins whose encoding gene is associated with this disease, reached through the canonical gene→disease graph. Number shows the gene's association score.
Reference
Authoritative identity, definition & identifiers.
APA with seizures and neurological abnormalities, Conn adenoma with seizures and neurological abnormalities, aldosterone-secreting adenoma with seizures and neurological abnormalities, complex neurodevelopmental disorder with or without aldosteronism, primary aldosteronism, seizures, and neurologic abnormalities, Conn adenoma, PASNA, aldosterone-secreting adenoma, aldosteronoma, primary aldosteronism due to Conn adenoma
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Related entities are derived from literature co-mention (studied together) — associative, not causal.